Joanie Pfahl and Jennifer Sutton explain the importance of informing and educating the patient, and why it is essential for nurses to have up-to-date knowledge.

Watch the video and download the slides


The GUIDE Communication Framework: Strengthening shared decision-making between nmCRPC patients and the healthcare team

This is the second in a series of three newsletters explaining the GUIDE Communication Framework, a simple 5-step approach to optimise the role of the nurse in strengthening shared decision-making between nmCRPC patients and their healthcare team.

GUIDE’s five letters each represent a crucial step in your conversations with patients with prostate cancer.

  • Gain insight into goals of treatment and care
  • Understand gaps in the patient's knowledge
  • Inform and educate
  • Direct to additional support
  • Empower the patient

Joanie Pfahl and Jennifer Sutton cover step 3 of the GUIDE Communication Framework and explain the importance of Informing and educating the patient, and why it is essential for nurses to have up-to-date knowledge about the disease and common symptoms, key studies relating to nmCRPC, treatment aims and options, potential side effects and proactive management as addressing patients’ knowledge gaps in the right way is critical in managing their treatment successfully.

In the first newsletter, Veerle Lamotte covered steps 1 and 2 of the GUIDE framework and explained why it’s important to Gain insight into the goals of treatment and care as a first step in supporting your patients along the agreed treatment journey and how to Understand the gaps in the patient’s knowledge, allowing you to prioritise where you focus when it comes to informing and educating the patient.

In the third newsletter, Jason Alcorn explains how to Direct the patient and the carer to additional support and the importance of Empowering the patient, making them feel they can actively participate in the shared decision-making and treatment process, and why these steps are an important part of a successful treatment journey.

Hello, my name is Joanie Pfahl. I am a resident nurse with the Atlantic Urology Clinics in Myrtle Beach, South Carolina. I’m going to talk about: Strengthening shared decision making between non-metastatic castrate-resistant prostate cancer patients and the healthcare team, and how we can use the GUIDE communication framework to support discussions with our patients.

Inform and educate the patient about treatment options

We will be focusing on step 3 of the framework, which includes how and what are the best ways to inform and educate the patient with regards to their treatment options. Since 2018, the treatment landscape for non-metastatic CRPC has changed with the approval of three next-generation oral androgen receptor inhibitors. They are apalutamide: SPARTAN trial, enzalutamide: PROSPER trial, and darolutamide with ARAMIS trial.

With the availability of the new AR target option, oncology nurses play a crucial role in the decision-making process; with educating, supporting, and to help the patients manage their prostate cancer. While ensuring they receive the most appropriate information to help their treatment decisions. It is essential that we educate and inform patients regarding their treatment aims for non-metastatic CRPC, and they are: prolong survival, delay metastasis, alleviation of tumour-related symptoms, balancing potential benefits against likely treatment toxicity, and maintaining quality of life.

While no head-to-head comparison of apalutamide, enzalutamide and darolutamide have been conducted to date, all three have demonstrated comparable efficacy and maintained quality of life in the SPARTAN, PROSPER and ARAMIS trials, but they have differing AE profiles. So why is the GUIDE communication framework needed?

Shared decision-making

Nurses are seen as the go-to person for their patients with non-metastatic CRPC, and therefore must empower patients with guidance and support, throughout their treatment journey, ensure patients are provided with the right information with their treatment decisions and to help fill in the gaps with their patient’s knowledge, and to be an active member of the healthcare team, in delivering shared decision-making, so they can provide patients with the greatest chance of success and meaningful, prolonged length of survival; to see their new grandchild, to attend a wedding, to attend a graduation or to plan a vacation.

Please go to gunursesconnect.cor2ed.com to take an in-depth look at the prepared slides and thank you for listening to the GU NURSES CONNECT.

Joanie Pfahl is a registered nurse working as the outpatient infusion nurse at Atlantic Urology Clinics (AUC) in Myrtle Beach, SC.  She received her Associate Degree in Nursing from Mount Aloysius College in Cresson, PA. Joanie has over 36 years of experience as a registered nurse in multiple areas including the intensive care unit, medical surgical unit, emergency room, pediatrics, and oncology.  Since November 2015, she has been administering chemotherapy and immunotherapy infusions to patients with genitourinary malignancies, which includes renal cell carcinoma, urothelial cancer, and advanced prostate cancer.  The unique position as the infusion nurse at AUC has been constantly evolving with the new advances of immunotherapy treatments.  Joanie has been adapting to the new treatment landscape by developing new policies and procedures for AUC, educating patients and their families on their treatments, managing adverse events, and coordinating patient care between multiple disciplinary areas of oncology. Joanie is a member of the Oncology Nursing Society and the Society of Urologic Nurses and Associates. As a member of the rapid response team at AUC, she has her Advanced Cardiac Life Support certification. Joanie has also served on multiple advisory boards for renal cell carcinoma and urothelial cancer.

Jennifer Sutton is a registered nurse and the Director of Nursing and Administration at Carolina Urologic Research Center in Myrtle Beach, SC.  After receiving her Bachelor of Science degree in Exercise Science with a minor in Chemistry from the University of South Carolina, she earned her Associate Degree in Nursing from Horry Georgetown Technical College. Jennifer is a member of the Society of Urologic Nurses and Associates, the Oncology Nursing Society, and the Association of Clinical Research Professionals (ACRP).   She is an ACRP-certified Clinical Research Coordinator and has more than 11 years of experience managing and administering cutting edge therapies to patients with genitourinary malignancies and other urologic disorders.  Additionally, she manages a team of research professionals that coordinate phase I-IV clinical trials in all areas of urology.  In recent years, she has served on multiple prostate cancer and bladder cancer advisory boards and has published articles on emerging prostate cancer treatments and effective structuring and management of a clinical research center. 

Jennifer Sutton has received financial support/sponsorship for research support, consultation, or speaker fees from the following companies:

Bayer, Janssen, Merck, Myovant and SeSen Bio. 

Programme summary
Watch the video now
Other episodes in this series
Share this programme
This educational programme is supported by an Independent Educational Grant from Bayer
I agree that this educational programme:

Was valuable to me

1/4
Brought to you by
GU NURSES CONNECT

GU NURSES CONNECT is an initiative of COR2ED, supported by Independent Educational Grants from AstraZeneca, Bayer, and Eisai Europe Limited.

Meet the experts Independent IME approved

Other programmes of interest

video Video
Oncology 
Recent advances in precision oncology and future implications

Two emerging and two established targets

Experts
Prof. David Hong
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
publication Publication
Oncology 
Survey on the evolving role of the oncology nurse in the USA

Announcing the publication of survey results 

Experts
Nina Grenon, Natasha Pinheiro, Karen Waldrop, Brittni Prosdocimo
  • download Downloadable
    Resources
  • clock 10 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Bayer.
video Video
Oncology 
Elacestrant in ER+/HER2- metastatic breast cancer

An expert overview of the EMERALD subgroup analysis

Experts
Dr Virginia Kaklamani
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

This programme has been sponsored by Menarini Stemline and is intended for healthcare professionals only.
video Video
Oncology 
Systemic treatment options for patients with non-clear cell renal cell carcinoma (nccRCC)

Managing patients with nccRCC: guidelines, recommendations, and best practice

Experts
Prof. Laurence Albiges
Endorsed by
Urobel VZW | ASBL
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Eisai Europe Limited (“Eisai”). Eisai has had no input on the educational content of, or speakers involved in this programme. 
micro-learning Micro learning
Oncology 
Metastatic pancreatic ductal adenocarcinoma (PDAC): from diagnosis to treatment

Risk factors, diagnostic tools and treatment options for different patient groups

Experts
Prof. Efrat Dotan, Prof. Shubham Pant
Endorsed by
Digestive Cancers Europe
  • download Downloadable
    Resources
  • clock 4 MIN
  • calendar Dec 2024

Educational programme supported by an Independent Educational Grant from Ipsen USA.
conference-update Conference update
Oncology 
Rezatapopt in TP53 Y220C mutated metastatic breast cancer: PYNNACLE phase 1/2 update

Exploring emerging treatment strategies presented at SABCS 2024

Experts
Prof. Frédérique Penault-Llorca, Dr Ecaterina E Dumbrava
  • download Downloadable
    Resources
  • clock 5 MIN
  • calendar Dec 2024

This programme has been sponsored by PMV Pharma.